METTL4和METTL5作为肝细胞癌患者无复发生存的生物标志物。
METTL4 and METTL5 as biomarkers for recurrence-free survival in hepatocellular carcinoma patients.
作者信息
Zhao Jialing, Sun Ruiqi, Zhi Liang, Guo Danjing, Ling Sunbin, Liang Xiangnan, Li Jianhui, Jia Changku
机构信息
Zhejiang University School of Medicine, Hangzhou, China.
Department of Hepatobiliary and Pancreatic Surgery, Hangzhou First People's Hospital, Hangzhou, China.
出版信息
Future Oncol. 2025 Feb;21(3):331-340. doi: 10.1080/14796694.2024.2442296. Epub 2024 Dec 20.
BACKGROUND
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths, with high rates of postoperative recurrence. Identifying reliable biomarkers for predicting recurrence is critical for improving patient outcomes. This study investigates the predictive value of m6A methylation-related genes, METTL4 and METTL5, on HCC recurrence after surgery.
RESEARCH DESIGN AND METHODS
We analyzed METTL4 and METTL5 expression in HCC and adjacent non-cancerous tissues using the TCGA database and evaluated their levels in surgical samples from 67 hCC patients. A recurrence risk model was developed and validated in an external cohort of 65 patients.
RESULTS
METTL4 and METTL5 were significantly overexpressed in HCC tissues. High expression correlated with shorter recurrence-free survival (RFS). The model stratified patients into high, medium, and low-risk groups with 3-year RFS rates of 18.75%, 69.70%, and 93.75%, respectively.
CONCLUSIONS
METTL4 and METTL5 expression levels are strong predictors of HCC recurrence. The risk model offers a novel approach for postoperative management of HCC.
背景
肝细胞癌（HCC）是癌症相关死亡的主要原因，术后复发率高。识别可靠的预测复发的生物标志物对于改善患者预后至关重要。本研究调查了m6A甲基化相关基因METTL4和METTL5对HCC术后复发的预测价值。
研究设计与方法
我们使用TCGA数据库分析了HCC组织和癌旁非癌组织中METTL4和METTL5的表达，并评估了67例HCC患者手术样本中的表达水平。在一个65例患者的外部队列中建立并验证了复发风险模型。
结果
METTL4和METTL5在HCC组织中显著过表达。高表达与无复发生存期（RFS）缩短相关。该模型将患者分为高、中、低风险组，3年RFS率分别为18.75%、69.70%和93.75%。
结论
METTL4和METTL
Zotero 插件